hit counter
Abeona Therapeutics Inc. (ABEO) Stock News Sentiment & Price - Sentifly
ABEO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Abeona Therapeutics Inc. (ABEO)

USA
Biotechnology
NASDAQ
ABEO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ABEO Latest news
GlobeNewsWire
Neutral
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
2021-10-21 07:30

NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021, at 3:30 p.m. ET.

GlobeNewsWire
Neutral
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
2021-10-13 07:30

NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The presentations include a poster presentation on the long-term wound healing and pain relief data from the Phase 1/2a EB-101 trial at the 2021 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, held virtually October 14-15, 2021; and an oral presentation on the pivotal trial of the Company's investigational AAV-based gene therapy ABO-102 in MPS IIIA at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), October 19-22, 2021.

GlobeNewsWire
Neutral
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
2021-10-12 07:30

NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice President, Head of Quality. Mr. Voss, who has been advising the Company as a consultant, will now serve in a leadership role to further strengthen Abeona's quality system and oversee all quality functions.

GlobeNewsWire
Neutral
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
2021-09-21 16:01

Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board

GlobeNewsWire
Neutral
Abeona Therapeutics to Present at Upcoming Investor Conferences
2021-09-07 07:30

NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company's management will present and conduct one-on-one meetings at the following virtual investor conferences:

GlobeNewsWire
Neutral
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
2021-08-10 07:30

NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective immediately. Mr. Carr had served as Abeona's Chief Accounting Officer since January 2019.

GlobeNewsWire
Neutral
Abeona Therapeutics Reports Second Quarter Financial Results
2021-07-28 16:01

Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study

Benzinga
Positive
Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy
2021-07-28 10:53

Abeona Therapeutics Inc (NASDAQ: ABEO) has completed a Type B meeting with the FDA regarding the pivotal trial for its ABO-102 gene therapy for Sanfilippo syndrome type A (MPS IIIA).  ABO-102 is currently being evaluated in the single-arm Transpher A study in patients with MPS IIIA.

GlobeNewsWire
Neutral
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
2021-07-28 07:30

Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease

Benzinga
Positive
Abeona Stock Moves Higher After MPS IIIA Gene Therapy Shows Increase In Brain Volume
2021-07-26 09:59

Abeona Therapeutics Inc (NASDAQ: ABEO) announced magnetic resonance imaging (MRI) data from the Phase 1/2 Transpher A study of ABO-102 gene therapy in Sanfilippo Syndrome Type A (MPS IIIA). Data indicated that ABO-102 increased grey matter, corpus callosum, and amygdala volumes in the brain in three young patients at 24 months as compared to afflicted patients without treatment.

Loading more news...